Skip to Main Content

Paper Details

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
Blood Adv
33
2022
Author NameAffiliation
Christoph R??lligUniversitatsklinikum Carl Gustav Carus
  • 1 - 1

Datasets

Release 1.2